NCT00903617 - Study to Test GSK256073 in Patients With Dyslipidemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 15, 2009

Primary Completion Date

February 16, 2010

Study Completion Date

February 16, 2010

Conditions

DyslipidaemiasDyslipidemias

Interventions

DRUG

GSK256073

5 mg for 8 weeks

DRUG

GSK256073

50 mg for 8 weeks

DRUG

GSK256073

150 mg for 8 weeks

DRUG

Placebo

placebo for 8 weeks

DRUG

Niaspan

1500 mg for 8 weeks

DRUG

GSK256073

x mg for 8 weeks based from data from Part A

DRUG

GSK256073

optional dose based on data from Part A

Trial Locations (11)

23294

GSK Investigational Site, Richmond

28677

GSK Investigational Site, Statesville

33026

GSK Investigational Site, Pembroke Pines

40213

GSK Investigational Site, Louisville

45246

GSK Investigational Site, Cincinnati

46260

GSK Investigational Site, Indianapolis

55430

GSK Investigational Site, Brooklyn Center

78205

GSK Investigational Site, San Antonio

98104

GSK Investigational Site, Seattle

98502

GSK Investigational Site, Olympia

04210

GSK Investigational Site, Auburn